Drug Trial Radar · NCT04923126
SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
132
Planned (sponsor's estimate)
Start
Jun 21, 2021
Primary completion
Jun 2031
Study completion Jun 2031
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- First posted
- Jun 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 years, up to 24 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multi-center, Phase 1/2 study of the brain-penetrant MEK inhibitor, mirdametinib (PD-0325901), in patients with pediatric low-grade glioma (pLGG).
Conditions
- Low-Grade Glioma
- Recurrent Low-Grade Glioma
- Progressive Low-Grade Glioma
Interventions
MirdametinibDrug
By mouth, nasogastric (NG) tube or gastrostomy tube (G-tube) BID, days 1-28
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Estimate the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of mirdametinib dosed twice daily on a continuous schedule in pediatric patients with progressive or recurrent low-grade glioma.Time frame: 1 month after start of mirdametinib treatment
- Phase 1: Determine the safety and tolerability of mirdametinib dosed twice daily on a continuous schedule in pediatric patients with progressive or recurrent low-grade glioma.Time frame: Up to 25 months after start of mirdametinib treatment
- Characterize the maximum plasma concentration and area under the concentration-time curve (AUC0-8h) of mirdametinib.Time frame: Course 1: Days 1 and 15
- Phase 2, Cohort 1: Objective response rate observed anytime during active treatment and sustained for at least 8 weeksTime frame: Up to 24 months after start of mirdametinib treatment
- Phase 2, Cohort 2: Objective response rate observed anytime during active treatment and sustained for at least 8 weeksTime frame: Up to 24 months after start of mirdametinib treatment
- Phase 2, Cohort 3a: Estimate 1-year disease stabilization rateTime frame: Up to 12 months (slight departures from this timing allowed based on MRI screening) after start of mirdamentinib treatment
- Phase 2, Cohort 3b: Estimate 6-month disease stabilization rateTime frame: Up to 6 months (slight departures from this timing allowed based on MRI screening) after start of mirdametinib treatment
- Describe the toxicity profile of mirdametinib by cohort.Time frame: Up to 25 months after start of mirdametinib treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.